National Pension Service Purchases 15,355 Shares of Cencora, Inc. $COR

National Pension Service grew its position in Cencora, Inc. (NYSE:COR) by 2.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 677,729 shares of the company’s stock after purchasing an additional 15,355 shares during the quarter. National Pension Service owned approximately 0.35% of Cencora worth $211,811,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Atlantic Edge Private Wealth Management LLC increased its stake in Cencora by 70.0% in the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after buying an additional 35 shares in the last quarter. Vermillion & White Wealth Management Group LLC boosted its stake in shares of Cencora by 69.4% in the second quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock worth $31,000 after acquiring an additional 43 shares during the period. Cloud Capital Management LLC purchased a new stake in shares of Cencora during the third quarter worth about $31,000. Copia Wealth Management raised its stake in Cencora by 505.0% during the 3rd quarter. Copia Wealth Management now owns 121 shares of the company’s stock valued at $38,000 after purchasing an additional 101 shares during the period. Finally, Caldwell Trust Co purchased a new position in Cencora in the 2nd quarter worth approximately $46,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Stock Performance

NYSE:COR opened at $359.14 on Friday. The firm has a market capitalization of $69.67 billion, a PE ratio of 45.17, a PEG ratio of 1.68 and a beta of 0.66. The stock’s fifty day moving average is $347.62 and its 200 day moving average is $324.08. Cencora, Inc. has a fifty-two week low of $237.71 and a fifty-two week high of $377.54. The company has a debt-to-equity ratio of 4.32, a quick ratio of 0.55 and a current ratio of 0.90.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. The business had revenue of $83.73 billion for the quarter, compared to analysts’ expectations of $83.36 billion. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The business’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, sell-side analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 14th were issued a $0.60 dividend. The ex-dividend date was Friday, November 14th. This is a positive change from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. Cencora’s dividend payout ratio (DPR) is currently 30.19%.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Robert W. Baird set a $415.00 price objective on shares of Cencora in a report on Tuesday, January 13th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Cencora in a report on Monday, December 29th. Barclays started coverage on shares of Cencora in a report on Monday, December 8th. They set an “overweight” rating and a $400.00 price objective for the company. Evercore ISI set a $400.00 target price on Cencora and gave the stock an “outperform” rating in a report on Thursday, November 6th. Finally, Jefferies Financial Group raised Cencora from an “underperform” rating to a “buy” rating in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $393.08.

Insider Buying and Selling

In related news, EVP Elizabeth S. Campbell sold 3,351 shares of the firm’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $342.10, for a total value of $1,146,377.10. Following the transaction, the executive vice president owned 23,891 shares of the company’s stock, valued at $8,173,111.10. This trade represents a 12.30% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Robert P. Mauch sold 5,096 shares of Cencora stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the sale, the chief executive officer owned 66,726 shares of the company’s stock, valued at $23,669,713.98. The trade was a 7.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 20,316 shares of company stock valued at $7,151,265. Insiders own 0.38% of the company’s stock.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.